Your SlideShare is downloading. ×
Gout therapeutics   pipeline assessment and market forecasts to 2019
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Gout therapeutics pipeline assessment and market forecasts to 2019

426
views

Published on

Published in: Business, Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
426
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Gout Therapeutics - Pipeline Assessment and Market Forecasts to2019GlobalData, the industry analysis specialist, has released its new report, “Gout Therapeutics - PipelineAssessment and Market Forecasts to 2019”. The report is an essential source of information and analysison the global Gout Therapeutics market. The report identifies the key trends shaping and driving theglobal Gout Therapeutics market. The report also provides insights on the prevalent competitivelandscape and the emerging players expected to significantly alter the market positioning of the currentmarket leaders. Most importantly, the report provides valuable insights on the pipeline products withinthe global Gout Therapeutics sector. This report is built using data and information sourced fromproprietary databases, primary and secondary research and in-house analysis by GlobalData’s team ofindustry experts.ScopeThe report provides information on the key drivers and challenges of the Gout Therapeutics market. Itsscope includes -  Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Gout Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.  Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.  Analysis of the current and future competition in the seven key countries Gout Therapeutics market.  Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.  Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Gout Therapeutics market.  Analysis of key recent licensing and partnership agreements in Gout Therapeutics marketGet your copy of this report @ http://www.reportsnreports.com/reports/165255-gout-therapeutics-pipeline-assessment-and-market-forecasts-to-2019.htmlReport Details:Published: June 2012No. of Pages: 80Price: Single User License: US$3995 Corporate User License: US$11985
  • 2. 1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Gout Therapeutics - Introduction 72.1 Disease Overview 72.2 Classification 72.2.1 Acute Gout 72.2.2 Chronic Gout 72.3 Epidemiology 82.3.1 Historic Epidemiology (2006-2011) 82.3.2 Forecast Epidemiology (2011-2019) 82.4 Prognosis 92.4.1 Progressions of Gout can be Divided into Four Phases 92.5 Pathophysiology 102.6 Signs and Symptoms 112.7 Diagnosis 112.7.1 Laboratory Diagnosis Tests 122.8 Treatment and Management Options 122.8.1 Treatment of Gout in the US 132.8.2 Treatment of Gout in Europe 152.8.3 Treatment of Gout in Japan 172.9 Referral Pathway 182.9.1 Referral Pathway in the US 182.9.2 Referral Pathway in the Europe 182.9.3 Referral Pathway in Japan 182.10 GlobalData Pipeline Report Guidance 192.11 KOL Insights 203 Gout Therapeutics - Market Characterization 213.1 Gout Therapeutics Market Size (2006-2011) – Global 213.2 Gout Therapeutics Market Forecast (2011-2019) – Global 223.3 Gout Therapeutics Market Size (2006-2011) – The US 233.4 Gout Therapeutics Market Forecast (2011-2019) – The US 243.5 Gout Therapeutics Market Size (2006-2011) – France 253.6 Gout Therapeutics Market Forecast (2011-2019) – France 263.7 Gout Therapeutics Market Size (2006-2011) – Germany 273.8 Gout Therapeutics Market Forecast (2011-2019) – Germany 283.9 Gout Therapeutics Market Size (2006-2011) – Italy 293.10 Gout Therapeutics Market Forecast (2011-2019) – Italy 303.11 Gout Therapeutics Market Size (2006-2011) – Spain 313.12 Gout Therapeutics Market Forecast (2011-2019) - Spain 323.13 Gout Therapeutics Market Size (2006-2011) – The UK 333.14 Gout Therapeutics Market Forecast (2011-2019) – The UK 343.15 Gout Therapeutics Market Size (2006-2011) – Japan 353.16 Gout Therapeutics Market Forecast (2011-2019) – Japan 36
  • 3. 3.17 Drivers and Barriers for the Gout Therapeutics Market 373.17.1 Drivers for the Gout Therapeutics Market 373.17.2 Expected Launch of Three Drugs and Consequent Increase in Cost of Therapy 373.17.3 Barriers for the Gout Therapeutics Market 373.18 Opportunity and Unmet Need Analysis 383.19 KOL Insight: 403.20 Key Takeaway 404 Gout Therapeutics - Competitive Assessment 414.1 Overview 414.2 Strategic Competitor Assessment 414.3 Product Profiles for the Major Marketed Classes of Products 424.3.1 NSAIDs 424.3.2 Corticosteroids 434.3.3 Colcrys (Colchicines) 434.3.4 Allopurinol 444.3.5 Probenecid 444.3.6 Uloric, Adenuric (febuxostat) 454.3.7 Krystexxa (Pegloticase) 464.4 KOL Insights 474.5 Key Takeaway 475 Gout Therapeutics - Pipeline Assessment 485.1 Overview 485.2 Strategic Pipeline Assessment 485.3 Gout Therapeutics Pipeline – Pipeline by Phases of Development 485.3.1 Gout Therapeutics – Pre-Registration Phase Pipeline 485.3.2 Gout Therapeutics – Phase III Pipeline 495.3.3 Gout Therapeutics – Phase II Pipeline 495.3.4 Gout Therapeutics – Phase I Pipeline 495.3.5 Gout Therapeutics – Pre-Clinical Pipeline 495.3.6 Gout Therapeutics – Discovery 505.3.7 Technology Trends Analytic Framework 505.4 Gout Therapeutics Market – Clinical Pipeline by Mechanism of Action 525.5 Gout Therapeutics – Promising Drugs Under Clinical Development 535.5.1 Arcalyst (Rilonacept) 535.5.2 Ilaris (ACZ885) 545.5.3 Lesinurad (RDEA594) 555.6 KOL Insights 565.7 Key Takeaway 566 Gout Therapeutics - Clinical Trials Mapping 576.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 576.2 Clinical Trials by Phase 586.3 Clinical Trials by Trial Status 596.4 Prominent Sponsors 60
  • 4. 6.5 Clinical Trials by Overall Sponsors 616.6 Top Companies Participating in Gout Therapeutics Clinical Trials 627 Gout Therapeutics - Strategic Assessment 637.1 Key Events Impacting the Future Market 637.2 Gout Therapeutics: Implications for Future Market Competition 648 Gout Therapeutics - Future Players 658.1 Introduction 658.2 Company Profiles 668.2.1 Regeneron Pharmaceuticals, Inc. 668.2.2 Novartis AG 668.2.3 Ardea Biosciences, Inc 678.2.4 Other Companies in the Market 689 Gout Therapeutics - Licensing and Partnership Deals 7010 KOL Insights 7411 Gout Therapeutics - Appendix 7511.1 Market Definitions 7511.2 Abbreviations 7511.3 Bibliography 7611.4 Research Methodology 7611.4.1 Coverage 7611.4.2 Secondary Research 7711.4.3 Forecasting 7711.4.4 Primary Research 7911.4.5 Expert Panel Validation 8011.5 Contact Us 8011.6 Disclaimer 80Browse all reports related to Pharmaceuticals @ http://www.reportsnreports.com/market-research/pharmaceuticals/Contact:TX, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441sales@reportsandreports.comConnect With Us: